Articles

A survey of T1D Exchange Clinic Registry participants found that some teens may be materially less likely than their younger peers to handle blood sugar emergencies. The findings were presented at the ADA 79th Scientific Sessions in San Francisco.

People with type 1 diabetes who already have anxiety, depression, or diabetes distress are more likely to also fear going low. This T1D Exchange-led research study was presented at the ADA 79th Scientific Sessions in San Francisco.

Read More About T1D Exchange Research at the ADA 79th Scientific Sessions

We provide links to articles about all 14 abstracts featuring T1D Exchange research and data from the T1D Exchange Clinic Registry.

Better Depression Screening and Higher CGM Adoption: Measuring Data at Diabetes Clinics

At the American Diabetes Association Scientific Sessions, the T1D Exchange Quality Improvement Collaborative shared early findings from efforts to standardize data collection and improve care at pediatric diabetes clinics.

Researchers with T1D Exchange Patient-Centered Research and Eli Lilly reported the results of six focus groups who discussed the daily burdens of life with type 1 diabetes.

Here are the 14 T1D Exchange Abstracts Presented at the American Diabetes Association 79th Scientific Sessions

Learn about researchers’ work to improve care and track health trends among people with type 1 diabetes.

T1D Exchange Clinic Registry Data Used in Many Studies Featured at the ADA 79th Scientific Sessions

We highlight a few that may have flown under the radar during the annual research extravaganza.

Tidepool Announces Partnership with Medtronic and Dexcom for Tidepool Loop

The goal is to create an interoperable automated insulin delivery device compatible with the Dexcom G6, as well as a future MiniMed pump or future Omnipod pump.

FDA Approves Eversense CGM for Non-Adjunctive Use

Users of the CGM soon will no longer need fingersticks to verify blood glucose readings before making management decisions.

Dual-Hormone iLet Bionic Pancreas Leads to Improvement in Glucose Levels in Small, In-Home Trial

Beta Bionics and Zealand Pharma announce positive Phase 2 results of a small trial of the dual-hormone system ahead of the ADA Scientific Sessions.